Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

@article{Scarabin1997EffectsOO,
  title={Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.},
  author={P. Scarabin and M. Alhenc-Gelas and G. Plu-Bureau and P. Taisne and R. Agher and M. Aiach},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  year={1997},
  volume={17 11},
  pages={
          3071-8
        }
}
Postmenopausal hormone replacement therapy is associated with a reduction in the incidence of coronary heart disease. However, inconclusive results have been reported with respect to the risk of stroke, and recent studies consistently showed an increased risk of venous thromboembolism in postmenopausal women using oral estrogen. There are surprisingly few interventional studies to assess the true effects of estrogen-progestin regimens on blood coagulation and fibrinolysis, and the impact of the… Expand

Paper Mentions

Interventional Clinical Trial
Primary purpose : Effects of two doses of hormone therapy on hsCRP. The effects of hormone replacement therapy on inflammatory markers are dose-dependent.  
ConditionsHealthy Symptomatic Menopausal Women
InterventionDrug
Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial.
TLDR
The data show that transdermal ERT as well as low dose of oral ERT does not significantly affect the homocysteine metabolism, and this finding does not support a role for transdermally estrogen in the prevention of ischaemic heart disease in postmenopausal women. Expand
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
TLDR
Low-dose oral estradiol therapy was associated with an increase in fibrinolysis and small decreases in procoagulant variables and transdermal therapy had minor effects. Expand
Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial
TLDR
The data show that oral, unlike transdermal, estrogen induces APC resistance and activates blood coagulation, and emphasize the importance of the route of estrogen administration. Expand
Changes in Hemostasis and Lipid Metabolism in Postmenopausal Women Receiving Hormone Replacement Therapy: Effects of Natural and Synthetic Progestogens
TLDR
Estrogen replacement therapy may have beneficial effects on lipid profile and fibrinolytic factors in postmenopausal women and both natural and synthetic progestogens attenuated the effects of estrogen. Expand
Changes in Hemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Administration in a Crossover-Designed Study
TLDR
Oral administration of estrogen statistically significantly reduced the tissue factor pathway inhibitor and plasminogen activator inhibitor-1 levels when compared with the transdermal route, and the zero change of D-dimers suggests that there was no activation of the coagulation cascade. Expand
Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women
  • K. Koh
  • Medicine
  • International journal of hematology
  • 2002
TLDR
HRT should not be initiated in women with established coronary artery disease or the coexistence of other risk factors for hypercoagulability-malignancy, immobility, obesity, diabetes, advanced age, or inherited traits, however, HRT at conventional dosages improves fibrinolysis potential in healthy postmenopausal women. Expand
Hormone therapy and hemostasis among postmenopausal women: a review
TLDR
Current knowledge on the effects of HT on hemostasis is summarized, taking into account the route of estrogen administration, the daily dose and chemical structure of estrogens, and the pharmacologic class of progestogens. Expand
The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study.
TLDR
Treatment with transdermal estradiol combined with long-cycle progestins was associated with no net activation of coagulation despite reduced levels of coAGulation inhibitors, and the effect of hormone replacement therapy on hemostasis was inconsistent. Expand
Estrogen and progestogen effect on venous thromboembolism in menopausal women
  • D. Archer, E. Oger
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2012
TLDR
Oral hormone therapy has been used principally for management of menopausal symptoms and transdermal estrogens have not been used as extensively in the United States but have a significant use in Europe. Expand
Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
TLDR
Transdermal HT avoids the first-pass effect of oestrogen in the liver and may have a less marked effect on the haemostatic system than equivalent oral preparations, which is investigated using two pharmacologically similar HT preparations which differed only in their route of administration. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women
TLDR
Changes in hemostatic variables of transdermal estradiol and oral equine conjugated estrogens combined with medroxyprogesterone acetate should be considered in a more extensive evaluation of the potential cardiovascular risk and benefits of hormone use. Expand
The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.
TLDR
To delineate and compare the effects of perorally administered conjugated estrogens (CE) and transdermally administered estradiol (E2) in doses needed for hormone replacement therapy (HRT) on haemostasis parameters, 23 postmenopausal women were engaged in a study with an open cross-over design. Expand
Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
TLDR
Estrogen alone or in combination with a progestin improves lipoproteins and lowers fibrinogen levels without detectable effects on postchallenge insulin or blood pressure and in women with a uterus, CEE with cyclic MP has the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia. Expand
Coagulation activation following estrogen administration to postmenopausal women.
TLDR
Data indicate that low doses of oral estrogens frequently increase the amount of thrombin generated in vivo, which may help to explain the increased thrombotic risk that has been observed with higher doses of this medication. Expand
Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
TLDR
It is suggested that the route of administration of E2 determines the biochemical response to ERT in postmenopausal women and SBP is the most sensitive marker of the liver action of estrogen, and triglycerides also are simple and useful markers for this effect. Expand
Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol.
OBJECTIVE To assess the effects of oral E2 replacement therapy combined with nomegestrol acetate, a 19-norprogesterone derivative, on cardiovascular risk factors. DESIGN A double-blind randomizedExpand
A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women.
TLDR
The lipid effects of estrogens in postmenopausal women probably prevent atherosclerosis, and it would expect long duration of use rather than current use to provide the greatest benefit, although few epidemiologic studies have assessed duration of estrogen use. Expand
Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone.
TLDR
It is concluded that physiologic estrogen replacement Therapy with or without added progesterone inhibits atherosclerosis progression in ovariectomized monkeys, which may explain why estrogen replacement therapy results in reduced risk of coronary heart disease in postmenopausal women. Expand
Haemostatic variables and menopausal status: influence of hormone replacement therapy.
TLDR
The findings suggest that 17-beta estradiol in combination with progestins may protect against an increased thrombotic tendency in postmenopausal women. Expand
Hormone replacement therapy and hemostasis: principles of a complex interaction.
TLDR
It is proposed to view the hemostatic system predominantly as a monitor of endothelial function rather than as a mediator of potential harmful effects on the cardiovascular system. Expand
...
1
2
3
4
5
...